Researchers test canine non-Hodgkin's lymphoma vaccine

10/19/2011 | ScienceDaily

Researchers from the University of Pennsylvania's schools of Medicine and Veterinary Medicine developed a vaccine for dogs with spontaneous non-Hodgkin's lymphoma that increased survival time. The vaccine uses the patient's own RNA and easy-to-isolate B-cells, as opposed to other attempts that used dendritic cells, which are cumbersome to produce. When relapse occurred after standard chemotherapy, 40% of the vaccinated dogs had long-term survival after a second round of chemotherapy, versus only 7% of non-vaccinated dogs.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC